AstraZeneca PLC ADR (AZN)

62.26
+0.49(+0.79%)
Pre Market
62.20
-0.06(-0.10%)
- Real-time Data
  • Volume:
    2,456,224
  • Bid/Ask:
    62.15/62.20
  • Day's Range:
    61.79 - 62.35

AZN Overview

Prev. Close
61.77
Day's Range
61.79-62.35
Revenue
29.53B
Open
61.93
52 wk Range
46.49-62.35
EPS
1.43
Volume
2,456,224
Market Cap
191.96B
Dividend (Yield)
1.40
(2.27%)
Average Volume (3m)
5,967,140
P/E Ratio
43.46
Beta
0.47
1-Year Change
17.32%
Shares Outstanding
1,549,135,894
Next Earnings Date
12 Nov 2021
What is your sentiment on AstraZeneca PLC ADR?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC ADR News

AstraZeneca PLC ADR Analysis

  • Top Pharma Stocks to Buy Now

    The stocks of the vaccine producers have gained a lot during 2021 due to the wide vaccination campaign around the world. Still, the COVID-19 pandemic is still not over as the virus...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

AstraZeneca PLC ADR Company Profile

AstraZeneca PLC ADR Company Profile

Employees
76100

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Read More
  • Thanks you AstraZ. Bullish. management services.
    0
    • 54 to 64 bullish sentiments again volatility trading
      0
      • $68 in 1 month
        4
        • Do you this will grow as EU has approved their Covid vaccine?
          0
          • will reach 100 in 6 months time
            0
            • I think the vaccine is nothing next to the antibody coctail, known as AZD7442 that Astra is working on at the momenthttps://www.reuters.com/article/health-coronavirus-astrazeneca-antibody-idUSKBN28100E
              0
              • Good buy in the long term.
                1
                • https://www.wsj.com/articles/astrazeneca-agrees-to-buy-alexion-for-39-billion-11607778687?redirect=amp#click=https://t.co/EeYlRyEn3g
                  0
                  • I expect it to reach $ 100 next month
                    1
                    • for super rich returns
                      0
                      • u need to hold it for a long term
                        0
                        • Attention , one of the trial subjects had serious implications , follow the news.
                          1
                          • AstraZeneca will be the best vaccine
                            0
                            • AZN are months ahead of their rivals - we’ll have a vaccine by October.
                              1
                              • Sinovac already had vaccine long before Moderna. But Moderna and Astrazenica have better global distribution...
                                0
                                • Interesting
                                  0
                                  • first Moderna second AstraZeneca to provide vaccine in short time
                                    2
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.